NCT04483206: Phase 1: Personalized Autologous Transplant for Multiple Myeloma
NCT03562169: Phase 3: Ixazomib in Autologous Stem Cell Transplant in RRMM Myeloma XII (ACCoRd)
NCT03412565: Phase 2 - Subcutaneous Daratumumab in Combination With Standard MM Regimens - PLEIADES
Ph 2: Carfilzomib & lenalidomide-based treatment for newly diagnosed primary plasma cell leukemia
NCT02197221: Phase 3: Bortezomib-Melphalan Conditioning Regimen vs Melphalan - Frontline Transplant
NCT02195479 : A Phase 3, Study of Bortezomib, Melphalan, Prednisone & Daratumumab ALCYONE trial
NCT01916252: Phase 3 - Bortezomib, Lenalidomide & IV Busulfan Under 65 - (GEM2012MENOS65) PETHEMA
NCT01729091: Phase 2: Umbilical Cord Blood-Derived NK Cells, Elotuzumab, Len, Melphalan f/b ASCT
NCT01208766: Phase 3 - EMN02 - Compare VMP With HDM f/b VRD Consol & Lenalidomide Maint. NDMM (HO95)
GMMG phase III trial ReLApsE Salvage autologous transplant and lenalidomide maintenance vs. len-Dex
NCT01093196: Phase 3: EMN01- Len/Dex Vs Melphalan/Pred/Len Vs Cyclophosamide/Pred/Len - elderly NDMM
NCT01191060: Phase 3 - IFM 2009 - (IFM/DFCI2009) Conventional dose RVD to High-Dose + ASCT -NDMM
NCT01190787: Phase 2: EMN - Velcade/Melphalan/Pred or Velcade/Cycloposphamide/Pred or Velcade/Pred.
NCT00734877: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myel
NCT00689936: Phase 3 - Lenalidomide+low dose dex vs Melphalan, Prednisone, Thalidomide in NDMM FIRST
NCT00747877: Phase 3: HDM and second HSCT or Low dose Dex in Myeloma RRMM - Myeloma X Relapse
NCT00602641: Phase 3: Melphalan, Prednisone, and Thalidomide or Lenalidomide in NDMM Myeloma
NCT00573391: Phase 3: Study of Multiple Myeloma Patients Relapsing or Progressing After ASCT -TT2
NCT00507416: Phase 3: Velcade,Thalidomide, Dexamethasone Vs Velcade, Dexamethasone Vs VMP (UPFRONT)